SEC Form 10-Q filed by Intellia Therapeutics Inc.
$NTLA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2024 | $136.00 → $32.00 | Buy → Neutral | Goldman |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 4/13/2023 | $66.00 | Buy | Canaccord Genuity |
| 3/21/2023 | $54.00 | Outperform | Bernstein |
| 3/14/2023 | $54.00 → $57.00 | Market Perform → Outperform | BMO Capital Markets |
| 2/1/2023 | $67.00 | Overweight | Cantor Fitzgerald |
| 1/24/2023 | $48.00 → $39.00 | Sell → Neutral | Citigroup |
| 1/19/2023 | Mkt Outperform → Mkt Perform | JMP Securities |
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-than-expected quarterly financial results. The finance behemoth reported second-quarter adjusted earnings per share of $1.51, beating the street view of $1.43. Quarterly revenue of $4.597 billion, an increase of 2% year-over-year, surpassed the analyst consensus of $4.523 billion, according to data from Benzinga Pro. Bank of New York Mellon shares surged 4.3% to $64.12 on Friday. Here are some other big stocks recording gains in today’s session. Lucid Group, Inc. (NASDAQ:LCID) sh
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company’s impressive second-quarter delivery numbers. The Tesla Trade Ark Invest reduced its stake in Tesla across its ARK Innovation ETF (NYSE:ARKK), selling 13,213 shares. This transaction came as a surprise, given that Tesla’s shares had recently soared 10.20% on Tuesday, marking the best intraday session since late April. Notably, on Tuesday, Ark Invest sold Tesla shares worth $14.5 million. The boost was primarily driven by the Elon Musk-led company’s second-quarter performance. Tesla reported 443,956 delive
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Technologies Inc (NYSE:PLTR). The Tesla Trade Ark Invest reduced its stake in Tesla across two of its ETFs — ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW). The firm sold 56,425 and 6,442 shares respectively, the transaction was valued at $14.54 million. On Tuesday, Tesla shares closed 10.2% higher at $231.26, driven higher by the second-quarter delivery report of the company. The numbers came ahead of the consensus estimate. This move comes despite Wood’s
10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-endStrong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans Plan to present new clinical data from the ongoing nex-z Phase 1 study at upcoming 2024 American Heart Association Scientific SessionsActively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE) Reported positive results from the Phase 2 study supporting NTLA-2002's potential to be a fun
Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November 16, at 11 a.m. CT / 12 p.m. ET CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November. Third Quarter 2024 Earnings – November 7, at 8 a.m. ETIntellia will present its third quarter 2024 financial results and operational highlights. To join the call, U.S. callers shoul
Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarterSelected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyOn track to initiate the Phase 3 study of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy by year-endPlan to present new clinical data from the ongoing NTLA-2001 Phase 1 in 2H 2024 Expect to dose the first patient in the Phase 1/2 study of N
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do
- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigat
Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-endStrong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans Plan to present new clinical data from the ongoing nex-z Phase 1 study at upcoming 2024 American Heart Association Scientific SessionsActively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE) Reported positive results from the Phase 2 study supporting NTLA-2002's potential to be a fun
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on November 1, 2024 it awarded inducement grants to ten new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for 73,459 shares of Intellia's common stock, with one-third of such RSUs vesting on November 1, 2025, 2026, and 2027. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Inte
Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November 16, at 11 a.m. CT / 12 p.m. ET CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November. Third Quarter 2024 Earnings – November 7, at 8 a.m. ETIntellia will present its third quarter 2024 financial results and operational highlights. To join the call, U.S. callers shoul
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
3 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
Goldman downgraded Intellia Therapeutics from Buy to Neutral and set a new price target of $32.00 from $136.00 previously
Wolfe Research initiated coverage of Intellia Therapeutics with a rating of Peer Perform
Canaccord Genuity initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $66.00